Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Vir Biotechnology Inc VIR

Healthcare Biotechnology
Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). It also has several preclinical... see more

Recent & Breaking News (NDAQ:VIR)

Nature Publishes New Research from Vir Biotechnology Demonstrating the Capacity of Enhanced Monoclonal Antibodies to Induce Protective Adaptive Immunity to Viral Infection

GlobeNewswire October 9, 2020

Vir Biotechnology and GSK announce global expansion to Phase 3 of COMET-ICE study evaluating VIR-7831 for the treatment of COVID-19

GlobeNewswire October 6, 2020

Vir Biotechnology Publishes New Research Characterizing Antibody Response to SARS-CoV-2 in the Journal Cell

GlobeNewswire September 24, 2020

Vir Biotechnology to Present at Cantor Global Virtual Healthcare Conference

GlobeNewswire September 9, 2020

Vir Biotechnology to Present at H.C. Wainwright 22nd Annual Global Investment Conference

GlobeNewswire September 8, 2020

Vir Biotechnology Appoints Janet Napolitano to its Board of Directors

GlobeNewswire September 1, 2020

Vir Biotechnology and GSK Start Phase 2/3 Study of COVID-19 Antibody Treatment

GlobeNewswire August 31, 2020

Vir Biotechnology Presents Data on VIR-2218 from Clinical Studies for the Treatment of Hepatitis B at the EASL Digital International Liver Congress(TM)

GlobeNewswire August 20, 2020

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2020 Financial Results

GlobeNewswire August 11, 2020

Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2020 Financial Results on August 11, 2020

GlobeNewswire July 28, 2020

Vir Biotechnology Appoints Elliott Sigal, M.D., Ph.D. to Board of Directors

GlobeNewswire July 10, 2020

Vir Biotechnology Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewswire July 10, 2020

Vir Biotechnology Announces Pricing of Public Offering of Common Stock

GlobeNewswire July 7, 2020

Vir Biotechnology Announces Proposed Public Offering of Common Stock

GlobeNewswire July 6, 2020

Vir Biotechnology and Biogen Execute Agreement to Manufacture SARS-CoV-2 Antibodies for Potential COVID-19 Treatment

GlobeNewswire May 29, 2020

Vir Biotechnology Initiates Phase 1 Clinical Trial of VIR-3434 for Chronic Hepatitis B Virus Infection

GlobeNewswire May 27, 2020

Identification and Characterization of a Potential Therapeutic COVID-19 Antibody by Vir Biotechnology Published in Nature

GlobeNewswire May 18, 2020

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2020 Financial Results

GlobeNewswire May 12, 2020

Vir Biotechnology Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders

GlobeNewswire May 8, 2020

Vir Biotechnology to Present at BofA Securities 2020 Health Care Conference

GlobeNewswire May 7, 2020